Posted 5/14/2015 1:22 PM (GMT 0)
Etrolizumab is Roche's me-too version of Entyvio. It's an anti-integrin that targets the same thing as Entyvio - alpha 4 beta 7. Don't worry about PML. Entyvio got slapped with the same warning. That is because of Tysabri, where there have actually been cases of PML. (There have been no cases with Entyvio.) Tysabri targets the more general alpha 4 (and all its betas), whereas Etrolizumab and Entyvio are more specific and do not cross into the central nervous system. That's why Tysabri also treats MS and the other two cannot, but it does make Tysabri more risky.
Anyway, good luck on the trial. But, I wonder, why are you not instead trying Entyvio, which you can start right now and does the same thing as Etrolizumab? If you go on a clinical trial there is a risk you'll get placebo.